Virus_Cells_Large.jpg
Nano_Vision.jpg
PeptineoOffices.jpg
Virus_Cells_Large.jpg

Reformulate


SCROLL DOWN

Reformulate


Are we entering the post-antibiotic era

Antibiotics are no longer as effective and as useful as before.  Methicillin-resistant Staphylococcus aureus (MRSA), extensively drug-resistant tuberculosis (XDR-TB), persistent infections associated with cystic fibrosis, etc. - all highlight a critical need in healthcare to develop new antibiotics now.  Innovative solutions to treat modern infections are starting to come on-line, but what about the current portfolio of antibiotics that are already available, and more importantly, already have regulatory approval?  Are these antibiotics still useful? What about this notion being floated in healthcare that suggests that we may actually be entering into the post-antibiotic era?  Is this true? Maybe…  In fact, it has been since 1987, almost 30 years ago, that a new class of antibiotics was approved for medical use.  Even more troubling has been the almost complete exit of Big Pharma from the development of antibiotics.  With no compelling financial incentive to develop life-saving drugs in this area, Big Pharma is no longer willing to invest when other areas like cancer offer much higher financial returns.  It’s not personal, it’s business…

Peptineo understands and has a solution to the impending antibiotic crisis.  In short, Peptineo will address this critical need for antibiotics in a very simple, yet elegant way by employing innovative reformulation.  How will this work? Peptineo has the ability to take poor performing or toxic antibiotics, combine them with a patented inactive ingredient, and re-introduce them as new formulations.  These new formulations will afford the medical community with to opportunity to extend the useful life of existing, approved antibiotics.  Additionally, these new formulations have a different, much shorter process for regulatory approval and subsequent medical use. Thus, Peptineo will re-formulate, expedite, and extend current antibiotics to fight against modern, drug-resistant infections. 

Nano_Vision.jpg

We Partner to Make Medicine Safer...


Acetalated Dextran (Ac-DEX) for Drug Delivery Applications.  Scroll down for brief video that describes Ac-DEX, its history, and use for therapeutic applications.

SCROLL DOWN

We Partner to Make Medicine Safer...


Acetalated Dextran (Ac-DEX) for Drug Delivery Applications.  Scroll down for brief video that describes Ac-DEX, its history, and use for therapeutic applications.

Our Approach

Peptineo is working to commercialize a novel nanomaterial, acetalated dextran (Ac-DEX), for tunable, controlled release drug delivery applications. This elegant technology was developed in the world famous lab of Jean Fréchet, PhD. Subsequently, the technology continued to be developed by one of its key inventors Eric Bachelder, PhD - with breakthrough innovations employing the technology being led by Kristy Ainslie, PhD. Most notably, this technology was employed as part of the recent high profile DARPA vaccine challenge -which was targeted against an unknown pathogen. Of note, Dr. Bachelder and Dr. Ainslie have now joined Peptineo as key scientific advisors.

Peptineo is now working to demonstrate that the over US$10M invested in research & development of Ac-DEX has produced a disruptive, breakthrough solution for drug delivery challenges faced in modern medicine.

Introducing FlexDEX - A platform for modern therapeutic delivery.

PeptineoOffices.jpg

Our Team


SCROLL DOWN

Our Team


Sheldon Jordan, PhD

President & Chief Executive Officer

Progressive leadership experience in government, semiconductor,  aerospace, and education/research sectors.  Managed engineering development and production activities with target contract values up to US$130 Million.

Leads overall company strategy, technology, marketing and vision.

Wojciech Ornatowski, PhD

Vice President, Research

Domain expertise in autophagy, neuroscience, pathogens, recombinant biology, instrumentation and mammalian cell line development. 

Leads company research & development and contract research activities.

Kimberley Beauford, MA

Vice President, Human Capital

Healthcare & Accounting industry veteran, business owner,  and entrepreneur.

Leads company human resource efforts.